Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.70 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | QPCT | Q16769 | 1/20 | 0.56 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.56 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722016 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL11265991 | 0.79 | CYP11B1 (0.75) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL10940697 | 0.79 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL11480633 | 0.76 | CYP11B1 (0.64) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL11023652 | 0.76 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL14416068 | 0.74 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL11085080 | 0.74 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL11270456 | 0.73 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL11107776 | 0.73 | CYP11B1 (0.65) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL10877264 | 0.73 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-3578981-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210231661-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-3803402-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Tudag Tu Dresden Aktiengesellschaft (DE) | 2021-04-14 | — | — | EP | disclosed |
| CN-112534265-A | Screening method for preselecting individual for anti-cancer treatment and identifying individual susceptible to disease | TUDAG德累斯顿工业大学股份公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2019233779-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Technische Universität Dresden (DE) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | CYP11B1 200/4885CYP11B2 191/4885CYP19A1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.